ImmuPharma (LON:IMM) Trading Up 4.1% - Here's What Happened

Key Points

• ImmuPharma shares rose by 4.1% during trading on Tuesday, reaching a last traded price of GBX 11.50 ($0.16), following a significant increase in trading volume.
• The company recently reported a negative earnings per share (EPS) of GBX (0.38) for the last quarter and has an expected EPS of around -339.00 for the current year.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, targeting the treatment of Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) was up 4.1% during trading on Tuesday . The company traded as high as GBX 14.20 ($0.19) and last traded at GBX 11.50 ($0.16). Approximately 20,334,650 shares traded hands during trading, an increase of 137% from the average daily volume of 8,565,097 shares. The stock had previously closed at GBX 11.05 ($0.15).

ImmuPharma Trading Up 9.5%

The business has a 50-day moving average price of GBX 4.46 and a 200 day moving average price of GBX 3.33. The stock has a market cap of £60.47 million, a PE ratio of -1,359.55 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, equities analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.